Shareholders meeting

Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji T +91 22 6060 9000 Road, Chakala, Andheri (E), E legal.info@ajantapharma.com Mumbai 400 093, India W www.ajantapharma.com 16th July 2026 BSE LIMITED National Stock Exchange of India, Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot no. Dalal Street, C/1, G Block, Bandra Kurla Complex, Mumbai – 400001 Bandra (East), Mumbai – 400 051 Scrip Code: BSE – AJANTPHARM 532331 Scrip Code: NSE AJANTPHARM EQ Re: Regulation 30 – Proceedings of Annual General Meeting Dear Sirs/Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith summary of proceedings of 47th Annual General Meeting of the Company held on 16th July 2026 through Video- conference/Other Audio-Visual Means. You are requested to kindly take above information on your records. Thanking You, Yours faithfully, Gaurang Shah Sr. VP – Legal and Company Secretary Encl.: a/a Corporate Identity Number - L24230MH1979PLC022059 Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji T +91 22 6060 9000 Road, Chakala, Andheri (E), E legal.info@ajantapharma.com Mumbai 400 093, India W www.ajantapharma.com SUMMARY OF PROCEEDINGS OF 47TH ANNUAL GENERAL MEETING 47th Annual General Meeting (AGM) of the Members of the Company was held on 16th July 2026 through Video-conference/Other Audio-Visual Means (VC/OAVM). The meeting commenced at 11.00 a.m. and concluded at 11.46 a.m. Mr. Mannalal Agrawal, Chairman of the Company, chaired the meeting. All the Directors including Chairman of the Audit Committee, the Nomination and Remuneration Committee and the Stakeholders’ Relationship Committee were present at the meeting. The representatives of the Statutory Auditors and the Secretarial Auditors were also present at the meeting. Number of shareholders present in the meeting through Video-conference: Promoter and Promoter Group Public Total 4 58 62 The Company Secretary, Mr. Gaurang Shah, stated that the meeting was conducted through VC / OAVM in compliance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. He also gave general instructions regarding participation in the meeting. Requisite quorum being present, the Chairman called the meeting to order. He welcomed members to the 47th AGM and requested the Managing Director to continue further proceedings. The Managing Director welcomed members and then other Directors, Statutory Auditor and Secretarial Auditor introduced themselves. The Managing Director then stated that Notice dated 5th May 2026, convening the 47th AGM and annual report for the year ended 31st March 2026 were already circulated to the members electronically and with the permission of members the same were taken as read. He mentioned that the audit reports of Statutory Auditors and Secretarial Auditors for the financial year 2025-2026, did not contain any qualifications or adverse remarks. The Managing Director then gave brief speech on performance of the Company and other important developments as well as achievements during the Financial Year 2025-2026. Thereafter, following items of business as set out in the Notice of the AGM, were tabled at the meeting for consideration of members and the Managing Director invited speakers who had registered their names for raising their queries and views on these items and the annual report. Corporate Identity Number - L24230MH1979PLC022059 Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji T +91 22 6060 9000 Road, Chakala, Andheri (E), E legal.info@ajantapharma.com Mumbai 400 093, India W www.ajantapharma.com # Particulars Resolution required 1. Adoption of Consolidated and Standalone Financial Ordinary Resolution Statements for the year ended 31st March 2026 2. Confirm interim dividend as final dividend Ordinary Resolution 3. Approve re-appointment of Mr. Mannalal B. Agrawal, Special Resolution retiring by rotation 4. Ratification of remuneration of Cost Auditors Ordinary Resolution Speaker shareholders were provided with facility through VC and Audio-Visual means, to put forth their queries, comments and views. Few shareholders put forth their queries and views which were responded by the Managing Director. The Managing Director then thanked all the shareholders for attending the meeting and for continued support for the Company. The Company Secretary then informed that the Company had provided remote e-voting facility through NSDL, to the shareholders to cast their votes electronically on all the resolutions set out in the Notice convening the meeting. Facility to vote through electronic voting system on all the items set out in the notice, was also made available at the meeting for those shareholders who had not cast their votes through remote e-voting before the meeting. He further stated that Company had appointed Mr. Pramod S. Shah & Associates, Practicing Company Secretary, as Scrutiniser for the purpose of scrutinising the process of remote e- voting held prior and e-voting during the AGM. The results of the remote e-voting and e- voting at the 47th AGM, together with the Report of the Scrutinisers thereon, will be disclosed to the Stock Exchanges and will be displayed on the website of the Company within two working days. For Ajanta Pharma Ltd. Gaurang Shah Sr. VP – Legal and Company Secretary Date: 16.07.2026 Corporate Identity Number - L24230MH1979PLC022059